Summary: SARcode
Bioscience, Inc., founded in 2006, is a venture-backed ophthalmic
biopharmaceutical company. SARcode’s lead development program is a novel class
of lymphocyte function-associated antigen-1 (LFA-1) antagonists for the
treatment T-cell mediated inflammatory diseases.
